|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The expression level of TOSO was significantly correlated with Binet staging, IGVH mutation status, age, and time to treatment in CLL.
|
21133733 |
2011 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In this study, using ChIP-sequencing, we identified EZH2 and H3K27me3 target genes in two prognostic subgroups of CLL with distinct prognosis and outcome, i.e., cases with unmutated (U-CLL, n = 6) or mutated IGHV genes (M-CLL, n = 6).
|
31216925 |
2019 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We retrospectively analyzed 463 patients with CLL with available immunoglobulin heavy-chain variable (IGHV) gene status and B-cell receptor (BCR) configuration [heavy-chain complementary-determining region 3 (HCDR3)], of whom thirty-six developed ITP, according to previously defined criteria.
|
22322667 |
2012 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53.
|
27109509 |
2016 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed the correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgVH), ZAP-70 and CD38 expression] and serum levels of B cell-activating factor (BAFF of the TNF family) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 169 previously untreated CLL patients in Binet stage A.
|
20546021 |
2010 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We previously identified LDOC1 as one of the most significantly differentially expressed genes in untreated chronic lymphocytic leukemia (CLL) patients with respect to the somatic mutation status of the immunoglobulin heavy-chain variable region genes.
|
21310924 |
2011 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The pattern and location of insertions/duplications or deletions in CLL and their restriction to mutated IGHV rearranged genes strongly suggests that they resulted from somatic hypermutation.
|
16783849 |
2006 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
To further characterize the biological features of this disease, we performed IgVH gene mutational status, FISH and high-resolution comparative genomic hybridization (HR-CGH) analysis in 17 cases of CLL/PL.
|
17410523 |
2007 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The two major subsets of CLL are biologically distinct, being derived from B cells at different stages of differentiation and carrying unmutated (U-CLL) or mutated (M-CLL) IGHV genes.
|
25048780 |
2014 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), are expressed in a recurrent fraction of patients affected by chronic lymphocytic leukemia (CLL).
|
21897877 |
2011 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
On a cohort of 110 patients with CLL treated with first-line fludarabin, cyclophosphamide, and rituximab treatment compared with 33 untreated (watch and wait) patients with CLL, we report more frequent complex karyotypes (34 vs 15%; P = .05), unmutated IGHV (70 vs 21%; P < .0001), ATM deletion (25 vs 6%, P = .02), and NOTCH mutation (3 vs 17%, P = .04).
|
27678008 |
2017 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, a single RNA-seq assay can simultaneously yield gene expression profile, SNP and mutation information, as well as IGHV mutation status, and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL.
|
25787252 |
2015 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes.
|
24924909 |
2014 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia.
|
21840049 |
2011 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes.
|
30283014 |
2018 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
To clarify the cellular origin of de novo CD5+ diffuse large B-cell lymphoma (CD5+ DLBL), particularly in comparison with other CD5+ B-cell neoplasms such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), we analyzed the nucleotide sequence of the Ig heavy chain variable region (IgVH) genes of de novo CD5+ DLBL cases.
|
9454743 |
1998 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Asians with CLL are younger, have atypical morphologic and immunologic features, an increased proportion of IGHV mutations and rearrangements and briefer freedom-from-progression than persons of predominately European descent with CLL.
|
25541495 |
2015 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
This is because the issue of the benefits of achieving MRD-negative status in patients with CLL requires further investigation in large controlled trials, in which patients should be stratified according to not only clinical variables but also biological parameters such as cytogenetics, IGHV mutations or ZAP-70 expression.
|
20620974 |
2010 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this work was to characterize hTERT splice variants in CLL in relation to disease activity, clinical stage, immunoglobulin heavy chain variable (IGHV) genes mutational status, and TL.
|
23548418 |
2013 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We herein suggest that the combined assessment of the IGHV mutational status and CK subtypes refines the prognostication of CLL, allowing to identify M-IGHV patients without any CK subtypes who are characterised by an indolent disease and excellent outcome after chemoimmunotherapy.
|
31209327 |
2019 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.
|
15466924 |
2005 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Finally, in certain instances, as in the case of chronic lymphocytic leukemia (CLL), the clonotypic IG sequence and, more specifically, the load of somatic hypermutations within the rearranged IG heavy variable (IGHV) gene, holds prognostic and potentially predictive value.
|
30350197 |
2019 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Here we demonstrate that some cases of B-CLL involved in lymph node carried mutated VH genes and showed intraclonal diversity like the tumor cells in the peripheral blood.
|
11699415 |
2001 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Plasma TPO and beta2-M may be useful for the prediction of clinical behavior in CLL and may replace the need for the determination of IgV(H) mutation status.
|
16551975 |
2006 |
|
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In addition to the mutation status of immunoglobulin variable heavy-chain region (IgVH) genes, which is a well-established predictive factor in B-CLL, these new markers include defects of cell factors involved in the maintenance of genome stability, such as telomere function, DNA repair, ATM and p53.
|
16753863 |
2006 |